Annual report pursuant to Section 13 and 15(d)

NATURE OF OPERATIONS AND SIGNIFICANT ACCOUNTING POLICIES (Details 7)

v3.6.0.2
NATURE OF OPERATIONS AND SIGNIFICANT ACCOUNTING POLICIES (Details 7)
$ / shares in Units, shares in Thousands, $ in Millions
Aug. 25, 2014
USD ($)
director
$ / shares
shares
Jun. 26, 2014
Strategic Alliance and Formation of China Joint Venture [Line Items]    
Premium to entity average stock price (as a percent)   10.00%
Fosun Pharma    
Strategic Alliance and Formation of China Joint Venture [Line Items]    
Shares issued (in shares) | shares 2,855  
Share price (in dollars per share) | $ / shares $ 16.19  
Period of time to measure premium of entity common stock   30 days
Related party ownership (as a percent) 15.00%  
Common Stock    
Strategic Alliance and Formation of China Joint Venture [Line Items]    
Dividends payable (in dollars per share) | $ / shares $ 1.50  
Dividends payable to shareholders $ 28.5  
Common Stock | Fosun Pharma    
Strategic Alliance and Formation of China Joint Venture [Line Items]    
Proceeds from issuance of private placement $ 44.8  
China Joint Venture    
Strategic Alliance and Formation of China Joint Venture [Line Items]    
Subsidiary or equity method investee, cumulative percentage owned (as a percent) 80.00%  
Initial capitalization amount $ 20.0  
China Joint Venture | Fosun Pharma    
Strategic Alliance and Formation of China Joint Venture [Line Items]    
Subsidiary or equity method investee, cumulative percentage owned (as a percent) 20.00%  
Initial capitalization amount $ 16.0  
Number of Board of Directors | director 1